CNS drug delivery studies, conducted in state-of-the-art facilities by the Pharmidex team, provide a comprehensive assessment of the concentration and duration of the test compound in brain ECF. The design of in-life experiments, coupled with clear and consistent data, will facilitate sound decision making for CNS drug discovery projects. Drug candidates can subsequently be developed and administered using Genzyme's novel and patented CNS delivery technology.
The drug delivery compounds are not chemically coupled to the drug candidate to be transported across the BBB and there are no other agents, polymers or medical devices involved. A wide range of small molecule drug candidates as well as larger peptides, proteins and antibodies have been successfully delivered across the BBB using the novel BBB drug delivery technology. Considerably enhanced therapeutic efficacy has been demonstrated with a number of drug candidates via neuro-pharmacokinetic studies. Extensive safety studies are underway in preparation for first use in human studies and the drug delivery compounds are readily manufactured at scale in a conventional GMP facility.
CerenseSM, therefore, provides a unique product development platform designed to unlock the potential of compounds constrained by poor BBB penetration, as well as opens new avenues for the creation of CNS medicines. Companies that overcome the twin obstacles, and develop CNS medicines with a good therapeutic ratio, stand to dominate this fastest growing sector of the pharmaceuticals market.
